Current review of Excimer laser Trabeculostomy

Durr, Georges M.; Töteberg-Harms, Marc; Lewis, Richard; Fea, Antonio; Marolo, Paola; Ahmed, Iqbal Ike K.

doi:10.1186/s40662-020-00190-7

Eye and Vision

Table 1 Excimer laser trabeculostomy: breakdown of current studies

From: Current review of Excimer laser Trabeculostomy

Authors	Type of study	Inclusion criteria	ELT spots	Study duration	Intervention/comparator	N of eyes	Preop IOP (mmHg)	Preop meds	Postop IOP (mmHg)	Postop meds
Randomized control trial
Babighian et al.	Prospective, comparative	Mild to moderate POAG	8	2 years	ELT	15	25 ± 1.9	2.3 ± 0.7	17.6 ± 2.2	0.7 ± 0.8
Babighian et al.	Prospective, comparative	Mild to moderate POAG	8	2 years	SLT	15	23.9 ± 0.9	2.2 ± 0.7	19.1 ± 1.8	0.9 ± 0.8
Prospective case series
Babighian et al.	Prospective nonrandomized trial, comparative	POAG	8	2 years	ELT	21	24.8 ± 2.0	2.24 ± 0.6	16.9 ± 2.1	0.71 ± 0.8
Babighian et al.	Prospective nonrandomized trial, comparative	POAG	8	2 years	Drops	21	21.67 ± 1.6	–	21.0 ± 0.5	–
Töteberg-Harms et al.	Prospective consecutive case series	OHT or mild to moderate OAG	10	1 year	ELT + CE	64	19.8 ± 5.3	2.4 ± 1.1	15.2 ± 4.4	1.5 ± 1.4
Berlin et al.^a	Prospective interventional case series	OAG	5–10	8 years	ELT	46	22.9 ± 5.4	1.6 ± 0.7	16.1 ± 3.4	1.2 ± 1.2
Berlin et al.^a	Prospective interventional case series	OAG	5–10	8 years	ELT + CE	37	25.1 ± 6.1	1.3 ± 0.7	14.2 ± 3.1	1.8 ± 0.8
Kleineberg et al.^a	Prospective observational study, comparative	Mild to moderate OAG	10	1 year	ELT + steroids	25	24.9 ± 2.7	2.0	17.0 ± 4.0	0.4
					ELT + NSAID	23	26.3 ± 2.5 (n = 23)	1.7 (n = 23)	16.0 ± 3.5 (n = 22)	0.6 (n = 22)
					ELT + CE	43	22.2 ± 1.7	1.4	12.0 ± 2.8	0.2
				5 years	ELT + steroids	25	24.9 ± 2.7 (n = 25)	2.0 (n = 25)	15.0 ± 3.2 (n = 15)	0.8 (n = 15)
					ELT + NSAID	23	26.3 ± 2.5 (n = 23)	1.7 (n = 23)	16.0 ± 2.6 (n = 15)	0.9 (n = 15)
					ELT + CE	43	22.2 ± 1.7 (n = 43)	1.4 (n = 43)	14.0 ± 2.6 (n = 31)	0.9 (n = 31)
Retrospective comparative study
Wilmsmeyer et al.	Retrospective case series, comparative	OHT or mild to moderate OAG	10	1 year	ELT	75	24.1 ± 0.7 (n = 69)	1.9 ± 0.1 (n = 69)	18.8 ± 0.8 (n = 37)	1.8 ± 0.2 (n = 37)
				1 year	ELT + CE	60	22.4 ± 0.6 (n = 57)	1.1 ± 0.2 (n = 57)	16.4 ± 0.4 (n = 35)	1.2 ± 0.2 (n = 35)
				2 years	ELT	75	24.1 ± 0.7 (n = 69)	1.9 ± 0.1 (n = 69)	16.8 ± 1.0 (n = 15)	1.5 ± 0.3 (n = 15)
				2 years	ELT + CE	60	22.4 ± 0.6 (n = 57)	1.1 ± 0.2 (n = 57)	12.8 ± 1.5 (n = 4)	1.8 ± 0.9 (n = 4)
Töteberg-Harms et al.	Retrospective interventional case series, comparative	Mild to moderate OAG	10	4 years	ELT + CE	51	19.0 ± 9.0 (n = 51) median ± IQR	2 ± 1 (n = 51)	14.0 ± 5.5 (n = 50)	1 ± 2 (n = 50)
Töteberg-Harms et al.	Retrospective interventional case series, comparative	Mild to moderate OAG	10	4 years	Trab+CE	62	22.8 ± 6.3 (n = 62)	2 ± 1 (n = 62)	14.0 ± 3.5 (n = 58)	0 (n = 58)
Jozic et al.	Retrospective interventional case series, comparative	OAG	10	1 year	CE	38	16.7 ± 3.8	1.1 ± 0.6	15.2 ± 3.1	1.0 ± 0.7
					ELT + CE	105	17.8 ± 4.3	1.4 ± 0.7	13.2 ± 2.3	0.5 ± 0.8
					ELT + Trabectome	102	19.3 ± 4.6	1.3 ± 0.8	13.8 ± 2.2	0.5 ± 0.7
Retrospective case series
Töteberg-Harms et al.	Retrospective case series	OHT or mild to moderate OAG	10	1 year	ELT + CE	28	25.3 ± 2.9	2.3 ± 1.3	16.5 ± 5.0	1.5 ± 1.4
Moreno Valladares et al.	Retrospective interventional case series	Mild to moderate OAG	10	6 months	ELT or ELT + CE	27	21.2	1.8	17.8	0.7

^aUnpublished studies
preop= preoperative; IOP= intraocular pressure; postop= postoperative; SD= standard deviation; IQR= interquartile range; POAG= primary open-angle glaucoma; OAG= open-angle glaucoma; OHT= ocular hypertension; NSAID= non-steroidal anti-inflammatory drug; ELT= Excimer laser trabeculostomy; CE= cataract Extraction; Trab= trabeculectomy.

Back to article page

ISSN: 2326-0254

Contact us

Submission enquiries: editorial@eandv.org
General enquiries: info@biomedcentral.com